Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma
Abstract Background Synovial sarcoma (SS) is an aggressive soft tissue tumor with limited therapeutic options in advanced stage. SS18-SSX fusion oncogenes, which are the hallmarks of SS, cause epigenetic rewiring involving histone deacetylases (HDACs). Promising preclinical studies supporting HDAC t...
Guardado en:
Autores principales: | Cinzia Lanzi, Enrica Favini, Laura Dal Bo, Monica Tortoreto, Noemi Arrighetti, Nadia Zaffaroni, Giuliana Cassinelli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/258ac722b6dc4231a4a62b0a9178a243 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer
por: Bingyi Zhou, et al.
Publicado: (2021) -
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
por: Tandon N, et al.
Publicado: (2016) -
Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: Jacob King, et al.
Publicado: (2021) -
The Potential Role of Epigenetic Drugs in the Treatment of Anxiety Disorders
por: Peedicayil J
Publicado: (2020) -
Nano-Assembly of Quisinostat and Biodegradable Macromolecular Carrier Results in Supramolecular Complexes with Slow-Release Capabilities
por: Ananda Chowdhury, et al.
Publicado: (2021)